How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Oncotarget
Główni autorzy: Pusceddu, Sara, De Braud, Filippo, Russo, Giuseppe Lo, Concas, Laura, Femia, Daniela, Vernieri, Claudio, Indini, Alice, Formisano, Barbara, Buzzoni, Roberto
Format: Artigo
Język:Inglês
Wydane: Impact Journals LLC 2016
Hasła przedmiotowe:
Review
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5190138/
https://ncbi.nlm.nih.gov/pubmed/27057638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8601
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy